REVEAL: A Phase 3 Study of ION582 in Angelman Syndrome
Status:
RECRUITING
Trial end date:
2030-04-01
Target enrollment:
Participant gender:
Summary
The purpose of this study is to evaluate the efficacy and safety of ION582 in children and adults with Angelman syndrome caused by a deletion or mutation of the UBE3A gene.